These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 23908358)

  • 1. Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia.
    Gagné V; Rousseau J; Labuda M; Sharif-Askari B; Brukner I; Laverdière C; Ceppi F; Sallan SE; Silverman LB; Neuberg D; Kutok JL; Sinnett D; Krajinovic M
    Clin Cancer Res; 2013 Sep; 19(18):5240-9. PubMed ID: 23908358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells.
    Jing D; Bhadri VA; Beck D; Thoms JA; Yakob NA; Wong JW; Knezevic K; Pimanda JE; Lock RB
    Blood; 2015 Jan; 125(2):273-83. PubMed ID: 25336632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-agent chemotherapy overcomes glucocorticoid resistance conferred by a BIM deletion polymorphism in pediatric acute lymphoblastic leukemia.
    Soh SX; Lim JY; Huang JW; Jiang N; Yeoh AE; Ong ST
    PLoS One; 2014; 9(8):e103435. PubMed ID: 25090024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.
    Ng KP; Hillmer AM; Chuah CT; Juan WC; Ko TK; Teo AS; Ariyaratne PN; Takahashi N; Sawada K; Fei Y; Soh S; Lee WH; Huang JW; Allen JC; Woo XY; Nagarajan N; Kumar V; Thalamuthu A; Poh WT; Ang AL; Mya HT; How GF; Yang LY; Koh LP; Chowbay B; Chang CT; Nadarajan VS; Chng WJ; Than H; Lim LC; Goh YT; Zhang S; Poh D; Tan P; Seet JE; Ang MK; Chau NM; Ng QS; Tan DS; Soda M; Isobe K; Nöthen MM; Wong TY; Shahab A; Ruan X; Cacheux-Rataboul V; Sung WK; Tan EH; Yatabe Y; Mano H; Soo RA; Chin TM; Lim WT; Ruan Y; Ong ST
    Nat Med; 2012 Mar; 18(4):521-8. PubMed ID: 22426421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and glucocorticoid-regulation of "Bam", a novel BH3-only transcript in acute lymphoblastic leukemia.
    Mansha M; Wasim M; Kofler A; Ploner C
    Mol Biol Rep; 2012 May; 39(5):6007-13. PubMed ID: 22237863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
    Hall CP; Reynolds CP; Kang MH
    Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.
    Bachmann PS; Piazza RG; Janes ME; Wong NC; Davies C; Mogavero A; Bhadri VA; Szymanska B; Geninson G; Magistroni V; Cazzaniga G; Biondi A; Miranda-Saavedra D; Göttgens B; Saffery R; Craig JM; Marshall GM; Gambacorti-Passerini C; Pimanda JE; Lock RB
    Blood; 2010 Oct; 116(16):3013-22. PubMed ID: 20647567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
    Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
    Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
    Nakagawa T; Takeuchi S; Yamada T; Ebi H; Sano T; Nanjo S; Ishikawa D; Sato M; Hasegawa Y; Sekido Y; Yano S
    Cancer Res; 2013 Apr; 73(8):2428-34. PubMed ID: 23382048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pro-apoptotic protein BIM in apoptosis of glucocorticoid-sensitive and -resistant acute lymphoblastic leukemia CEM cells.
    Zhao YN; Guo X; Ma ZG; Gu L; Ge J; Li Q
    Med Oncol; 2011 Dec; 28(4):1609-17. PubMed ID: 20697841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner.
    Kazi A; Sun J; Doi K; Sung SS; Takahashi Y; Yin H; Rodriguez JM; Becerril J; Berndt N; Hamilton AD; Wang HG; Sebti SM
    J Biol Chem; 2011 Mar; 286(11):9382-92. PubMed ID: 21148306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BIM is a prognostic biomarker for early prednisolone response in pediatric acute lymphoblastic leukemia.
    Jiang N; Koh GS; Lim JY; Kham SK; Ariffin H; Chew FT; Yeoh AE
    Exp Hematol; 2011 Mar; 39(3):321-9, 329.e1-3. PubMed ID: 21130142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-deoxyglucose-induced toxicity is regulated by Bcl-2 family members and is enhanced by antagonizing Bcl-2 in lymphoma cell lines.
    Zagorodna O; Martin SM; Rutkowski DT; Kuwana T; Spitz DR; Knudson CM
    Oncogene; 2012 May; 31(22):2738-49. PubMed ID: 21986940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FoxO proteins' nuclear retention and BH3-only protein Bim induction evoke mitochondrial dysfunction-mediated apoptosis in berberine-treated HepG2 cells.
    Shukla S; Rizvi F; Raisuddin S; Kakkar P
    Free Radic Biol Med; 2014 Nov; 76():185-99. PubMed ID: 25128467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGFbeta-mediated apoptosis of Burkitt's lymphoma BL41 cells is associated with the relocation of mitochondrial BimEL.
    Clybouw C; Mchichi BE; Hadji A; Portier A; Auffredou MT; Arnoult D; Leca G; Vazquez A
    Oncogene; 2008 May; 27(24):3446-56. PubMed ID: 18193085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.
    Peter B; Cerny-Reiterer S; Hadzijusufovic E; Schuch K; Stefanzl G; Eisenwort G; Gleixner KV; Hoermann G; Mayerhofer M; Kundi M; Baumgartner S; Sperr WR; Pickl WF; Willmann M; Valent P
    J Leukoc Biol; 2014 Jan; 95(1):95-104. PubMed ID: 24052572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM.
    Rambal AA; Panaguiton ZL; Kramer L; Grant S; Harada H
    Leukemia; 2009 Oct; 23(10):1744-54. PubMed ID: 19404317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor.
    Bachmann PS; Gorman R; Mackenzie KL; Lutze-Mann L; Lock RB
    Blood; 2005 Mar; 105(6):2519-26. PubMed ID: 15572593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
    San José-Eneriz E; Agirre X; Jiménez-Velasco A; Cordeu L; Martín V; Arqueros V; Gárate L; Fresquet V; Cervantes F; Martínez-Climent JA; Heiniger A; Torres A; Prósper F; Roman-Gomez J
    Eur J Cancer; 2009 Jul; 45(10):1877-89. PubMed ID: 19403302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of cytokine withdrawal-induced apoptosis by Mcl-1 requires interaction between Mcl-1 and Bim.
    Jamil S; Wang SW; Bondy L; Mojtabavi S; Duronio V
    Biochem Cell Biol; 2010 Oct; 88(5):809-18. PubMed ID: 20921992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.